Real time insider trading transaction history:
- Insiders are prohibited from making short-swing profits by trading their shares within 6 months of the registration or acquiring the shares.
- Shares are not adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
Common stock purchase or sale:
| Transaction Date |
Reported DateTime |
Company | Symbol | Insider Relationship |
Shares Traded |
Average Price |
Total Amount |
Shares Owned |
Filing |
| 2021-12-13 Purchase |
2021-12-15 8:17 pm |
Revance Therapeutics Inc. | RVNC | Russell Angus C. Director |
6,400 | $15.74 | $100,741 | 26,913 (Direct) |
View |
| 2021-12-03 Purchase |
2021-12-06 8:34 pm |
Revance Therapeutics Inc. | RVNC | Rankin Aubrey President, Innovation & Tech |
30,000 | $14.43 | $432,876 | 571,376 (Indirect Direct) |
View |
| 2021-11-29 Purchase |
2021-11-29 9:24 pm |
Revance Therapeutics Inc. | RVNC | Foley Mark J CEO |
40,000 | $12.9 | $515,924 | 879,978 (Indirect Direct) |
View |
| 2021-09-27 Sale |
2021-09-28 9:23 pm |
Revance Therapeutics Inc. | RVNC | Moxie Dwight SVP, GC & Secretary |
1,675 | $30 | $50,250 | 47,804 (Direct) |
View |
| 2021-08-16 Sale |
2021-08-17 6:20 pm |
Revance Therapeutics Inc. | RVNC | Rankin Aubrey President, Innovation & Tech |
9,364 | $26.34 | $246,659 | 541,376 (Indirect Direct) |
View |
| 2021-07-28 Sale |
2021-07-30 8:57 pm |
Revance Therapeutics Inc. | RVNC | Rankin Aubrey President, Innovation & Tech |
54,332 | $30.06 | $1,632,960 | 234,078 (Indirect Direct) |
View |
| 2021-07-26 Sale |
2021-07-28 9:48 pm |
Revance Therapeutics Inc. | RVNC | Rankin Aubrey President, Innovation & Tech |
55,382 | $29.72 | $1,645,953 | 610,021 (Indirect Direct) |
View |
| 2021-04-05 Sale |
2021-04-06 7:41 pm |
Revance Therapeutics Inc. | RVNC | Rankin Aubrey President, Innovation & Tech |
2 | $28.28 | $57 | 665,403 (Indirect Direct) |
View |
| 2021-03-04 Sale |
2021-03-05 8:10 pm |
Revance Therapeutics Inc. | RVNC | Rankin Aubrey President, Innovation & Tech |
33,119 | $25.43 | $842,216 | 665,405 (Indirect Direct) |
View |
Stock options: Exercise, Award, Grant, Conversion
| Transaction Date |
Reported DateTime |
Exercisable Expiration |
Company | Symnbol | Insider Relationship |
Shares Traded |
Conversion Price |
Shares Owned |
Filing |
| 2022-02-15 Tax Withholding |
2022-02-17 8:54 pm |
N/A N/A |
Revance Therapeutics Inc. | RVNC | Sjuts Dustin S President |
2,429 | $13.35 | 98,958 (Direct) |
View |
| 2022-02-15 Tax Withholding |
2022-02-17 8:51 pm |
N/A N/A |
Revance Therapeutics Inc. | RVNC | Joshi Abhay COO, President, R&D |
5,053 | $13.35 | 123,315 (Direct) |
View |
| 2022-02-15 Tax Withholding |
2022-02-17 8:49 pm |
N/A N/A |
Revance Therapeutics Inc. | RVNC | Schilke Tobin CFO |
2,924 | $13.35 | 65,132 (Direct) |
View |
| 2022-02-02 Option Award |
2022-02-04 8:38 pm |
N/A 2032-02-01 |
Revance Therapeutics Inc. | RVNC | Sjuts Dustin S President |
57,016 | $0 | 57,016 (Direct) |
View |
| 2022-02-02 Option Award |
2022-02-04 8:36 pm |
N/A 2032-02-01 |
Revance Therapeutics Inc. | RVNC | Moxie Dwight SVP, GC & Secretary |
68,093 | $0 | 68,093 (Direct) |
View |
| 2022-02-02 Option Award |
2022-02-04 8:35 pm |
N/A 2032-02-01 |
Revance Therapeutics Inc. | RVNC | Foley Mark J CEO |
143,354 | $0 | 143,354 (Direct) |
View |
| 2022-02-02 Option Award |
2022-02-04 8:31 pm |
N/A 2032-02-01 |
Revance Therapeutics Inc. | RVNC | Schilke Tobin CFO |
68,093 | $0 | 68,093 (Direct) |
View |
| 2021-12-31 Other |
2022-01-04 8:58 pm |
N/A N/A |
Revance Therapeutics Inc. | RVNC | Schilke Tobin CFO |
404 | $13.87 | 68,460 (Direct) |
View |
| 2021-12-15 Tax Withholding |
2021-12-17 5:31 pm |
N/A N/A |
Revance Therapeutics Inc. | RVNC | Schilke Tobin CFO |
1,556 | $15.92 | 67,652 (Direct) |
View |
| 2021-12-15 Tax Withholding |
2021-12-17 5:29 pm |
N/A N/A |
Revance Therapeutics Inc. | RVNC | Sjuts Dustin S President |
513 | $15.92 | 101,387 (Direct) |
View |
| 2021-11-09 Option Award |
2021-11-10 8:32 pm |
N/A N/A |
Revance Therapeutics Inc. | RVNC | Sjuts Dustin S President |
35,920 | $0 | 101,900 (Direct) |
View |
| 2021-10-13 Tax Withholding |
2021-10-15 8:00 pm |
N/A N/A |
Revance Therapeutics Inc. | RVNC | Foley Mark J CEO & President |
42,096 | $23.08 | 839,978 (Direct) |
View |
| 2021-08-15 Tax Withholding |
2021-08-17 6:20 pm |
N/A N/A |
Revance Therapeutics Inc. | RVNC | Rankin Aubrey President, Innovation & Tech |
4,949 | $26.02 | 541,376 (Direct) |
View |
| 2021-06-30 Other |
2021-07-02 7:56 pm |
N/A N/A |
Revance Therapeutics Inc. | RVNC | Sjuts Dustin S Chief Commercial Officer |
882 | $24.09 | 66,862 (Direct) |
View |
| 2021-06-30 Other |
2021-07-02 7:53 pm |
N/A N/A |
Revance Therapeutics Inc. | RVNC | Schilke Tobin CFO |
446 | $24.09 | 69,654 (Direct) |
View |
| 2021-06-30 Other |
2021-07-02 7:52 pm |
N/A N/A |
Revance Therapeutics Inc. | RVNC | Foley Mark J CEO & President |
882 | $24.09 | 882,956 (Direct) |
View |
| 2021-05-05 Option Award |
2021-05-07 7:23 pm |
N/A 2031-05-04 |
Revance Therapeutics Inc. | RVNC | Ware Olivia C Director |
1,942 | $0 | 8,350 (Direct) |
View |
| 2021-05-05 Option Award |
2021-05-07 7:15 pm |
N/A 2031-05-04 |
Revance Therapeutics Inc. | RVNC | Vickers Philip J. Director |
11,564 | $0 | 31,214 (Direct) |
View |
| 2021-05-05 Option Award |
2021-05-07 7:12 pm |
N/A 2031-05-04 |
Revance Therapeutics Inc. | RVNC | Russell Angus C. Director |
11,564 | $0 | 28,064 (Direct) |
View |
| 2021-05-05 Option Award |
2021-05-07 7:10 pm |
N/A 2031-05-04 |
Revance Therapeutics Inc. | RVNC | Nolet Chris Director |
11,564 | $0 | 26,564 (Direct) |
View |
| 2021-05-05 Option Award |
2021-05-07 7:08 pm |
N/A 2031-05-04 |
Revance Therapeutics Inc. | RVNC | Kolaja Carey OConnor Director |
1,942 | $0 | 8,236 (Direct) |
View |
| 2021-05-05 Option Award |
2021-05-07 7:06 pm |
N/A 2031-05-04 |
Revance Therapeutics Inc. | RVNC | Gangolli Julian S Director |
11,564 | $0 | 28,064 (Direct) |
View |
| 2021-05-05 Option Award |
2021-05-07 7:04 pm |
N/A 2031-05-04 |
Revance Therapeutics Inc. | RVNC | Beraud Jill Director |
11,564 | $0 | 26,564 (Direct) |
View |
| 2021-04-15 Tax Withholding |
2021-04-16 8:17 pm |
N/A N/A |
Revance Therapeutics Inc. | RVNC | Sjuts Dustin S Chief Commercial Officer |
411 | $28.16 | 65,098 (Direct) |
View |
| 2021-03-15 Tax Withholding |
2021-03-17 7:29 pm |
N/A N/A |
Revance Therapeutics Inc. | RVNC | Moxie Dwight SVP, GC & Secretary |
2,881 | $27.73 | 49,479 (Direct) |
View |
| 2021-03-15 Tax Withholding |
2021-03-17 7:27 pm |
N/A N/A |
Revance Therapeutics Inc. | RVNC | Joshi Abhay COO, President, R&D |
1,354 | $27.73 | 128,368 (Direct) |
View |
| 2021-03-08 Option Award |
2021-03-10 7:13 pm |
N/A 2031-03-07 |
Revance Therapeutics Inc. | RVNC | Ware Olivia C Director |
17,569 | $0 | 17,569 (Direct) |
View |
| 2021-03-01 Option Award |
2021-03-02 8:17 pm |
N/A 2031-02-28 |
Revance Therapeutics Inc. | RVNC | Kolaja Carey OConnor Director |
17,711 | $0 | 17,711 (Direct) |
View |
| 2021-02-15 Tax Withholding |
2021-02-19 8:15 pm |
N/A N/A |
Revance Therapeutics Inc. | RVNC | Schilke Tobin CFO |
2,657 | $28.97 | 68,762 (Direct) |
View |
| 2021-02-15 Tax Withholding |
2021-02-19 8:13 pm |
N/A N/A |
Revance Therapeutics Inc. | RVNC | Sjuts Dustin S Chief Commercial Officer |
2,410 | $28.97 | 65,509 (Direct) |
View |